Paris, France - Astraveus, a pioneering biotechnology company based in Paris, Ile-de-France, announced today that it has successfully raised $18,069,727 in a seed funding round. The investment was led by Bpifrance Large Venture, M Ventures, and AdBio partners, prominent investors known for their strategic support in the biotech industry.

Astraveus aims to transform the field of CGT (Cell and Gene Therapy) manufacturing with its groundbreaking Lakhesys™ platform. This cutting-edge technology represents an end-to-end cell foundry that leverages deep process optimization and utilizes single-use, microfluidic bioprocessors to achieve superior outcomes while reducing resource consumption.

The traditional challenges associated with CGT manufacturing, such as the need for extensive infrastructure, high costs, and logistical hurdles, are effectively addressed by Astraveus's innovative approach. By eliminating the reliance on large-scale facilities and streamlining operations, the company strives to revolutionize patient access to life-changing therapies.

"We are thrilled to have secured this significant investment in our seed round," said Jérémie Laurent, Founder of Astraveus. "The support from Bpifrance Large Venture, M Ventures, and AdBio partners validates our vision and highlights the potential impact of our Lakhesys™ platform in advancing CGT manufacturing. This funding will enable us to continue driving innovation, delivering improved therapeutic solutions, and transforming the lives of patients."